VA
APGE icon

VR Adviser’s Apogee Therapeutics APGE Stock Holding History

VR Adviser’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13B Hold
8,493,321
– – 34.18% 1
2026
Q1 		$715M Hold
8,493,321
– – 26.68% 1
2025
Q4 		$641M Hold
8,493,321
– – 31.67% 1
2025
Q3 		$337M Hold
8,493,321
– – 18.99% 1
2025
Q2 		$369M Hold
8,493,321
– – 27.64% 1
2025
Q1 		$317M Hold
8,493,321
– – 27% 1
2024
Q4 		$385M Hold
8,493,321
– – 26.4% 1
2024
Q3 		$499M Hold
8,493,321
– – 26.13% 1
2024
Q2 		$334M Hold
8,493,321
– – 21.28% 1
2024
Q1 		$564M Hold
8,493,321
– – 26.85% 1
2023
Q4 		$237M Hold
8,493,321
– – 16.28% 2
2023
Q3 		$181M Buy
+8,493,321
New +$187M 19.04% 1

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

VR Adviser's APGE Position: Q2 2026 in Review

VR Adviser held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 8,493,321 shares worth $1.13B. The position accounts for 34.18% of the portfolio, ranked #1.

VR Adviser first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • VR Adviser held 8,493,321 shares of Apogee Therapeutics worth $1.13B as of Q2 2026.
  • VR Adviser left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up 34.18% of VR Adviser's portfolio in Q2 2026, its #1 holding.
  • VR Adviser first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.